Download pdf
Applications of Nanotechnology in the Treatment of Alzheimer’s Disease
- 1 The University of Sydney, Faculty of Medicine and Health, School of Medical Sciences, Camperdown, NSW, 2006, Australia
* Author to whom correspondence should be addressed.
Abstract
Alzheimer’s Disease (AD) is a neurodegenerative disease associated with progressive memory and cognitive impairment. Due to the devastating social and financial impacts of AD, extensive research is put into gaining a clearer understanding of its pathogenesis and risk factors, as well as the development of treatments that can slow or reverse the disease progression. Despite this, early and accurate detection of AD and the development of curative treatments are yet to be achieved. Further, major challenges remain in the symptomatic treatments available today, as the delivery of Alzheimer’s medications is limited by low efficiency due to difficulties in blood-brain barrier permeation and poor absorption. The incorporation of nanotechnology in current and potential treatments present unique opportunities for the delivery of therapeutic agents with increased specificity, lower toxicity and controlled release. In this review, we outline the proposed pathogenesis, current diagnosis and treatment methods of AD, and discuss recent advancements in nanomaterial-based systems that target major hallmarks of AD through different mechanisms, including targeted drug delivery, inhibition of Aβ aggregation, delivery of neuroprotective agents and Aβ removal from the blood.
Keywords
Nanotechnology, Drug Delivery, Alzheimer’s Disease
[1]. Dementia. n.d. https://www.who.int/news-room/fact-sheets/detail/dementia (accessed October 5, 2022).
[2]. E. Nichols, J.D. Steinmetz, S.E. Vollset, K. Fukutaki, J. Chalek, F. Abd-Allah et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet Public Health 2022;7:e105–25.
[3]. L.A. Farrer. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis. JAMA 1997;278:1349.
[4]. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis. Science 2003a;300:486–9.
[5]. K.R. Wildsmith, M. Holley, J.C. Savage, R. Skerrett, G.E. Landreth. Evidence for impaired amyloid β clearance in Alzheimer’s disease. Alzheimers Res Ther 2013;5:33.
[6]. L. Muzio, A. Viotti, G. Martino. Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy. Front Neurosci 2021;15:742065.
[7]. A. González, S.K. Singh, M. Churruca, R. B. Maccioni. Alzheimer’s Disease and Tau Self-Assembly: In the Search of the Missing Link. IJMS 2022;23:4192.
[8]. S. Baldwin, S.T. Farias. Neuropsychological assessment in the diagnosis of alzheimer's disease. Current Protocols in Neuroscience. 2009;49(1).
[9]. B. Dubois, H.H. Feldman, C. Jacova, H. Hampel, J.L. Molinuevo, K. Blennow, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. The Lancet Neurology 2014;13:614–29.
[10]. J.P. Lerch, J.C. Pruessner, A. Zijdenbos, H. Hampel, S.J. Teipel, A.C. Evans. Focal decline of cortical thickness in alzheimer's disease identified by Computational Neuroanatomy. Cerebral Cortex. 2004;15(7):995–1001.
[11]. R. Camicioli, M. M. Moore, A. Kinney, E. Corbridge, K. Glassberg, J.A. Kaye. Parkinson's disease is associated with hippocampal atrophy. Movement Disorders. 2003;18(7):784–90.
[12]. A.S. Fleisher, M.J. Pontecorvo, M.D. Devous, M. Lu, A.K. Arora, S.P.Truocchio, et al. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol 2020;77:829–39.
[13]. D. Knopman, D. Jones, M. Greicius. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimer's & Dementia. 2020;17(4):696-701.
[14]. H. Kadry, B. Noorani, L. Cucullo. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids and Barriers of the CNS. 2020;17(1).
[15]. S. Ohta, E. Kikuchi, A. Ishijima, T. Azuma, I. Sakuma, T. Ito. Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood–brain barrier opening. Scientific Reports. 2020;10(1).
[16]. J. Suk, Q. Xu, N. Kim, J. Hanes, L. Ensign. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced Drug Delivery Reviews. 2016;99:28-51.
[17]. W. Li, Y. Zhou, N. Zhao, B. Hao, X. Wang, P. Kong. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environmental Toxicology and Pharmacology. 2012;34(2):272-279.
[18]. M. Peralta, M. Guzmán, A. Pérez, G. Apezteguia, M. Fórmica, E. Romero et al. Liposomes can both enhance or reduce drugs penetration through the skin. Scientific Reports. 2018;8(1).
[19]. M. Fernandes, I. Lopes, L. Magalhães, M. Sárria, R. Machado, J. Sousa et al. Novel concept of exosome-like liposomes for the treatment of Alzheimer's disease. Journal of Controlled Release. 2021;336:130-143.
[20]. S. Semple, S. Klimuk, T. Harasym, N. Dos Santos, S. Ansell, K. Wong et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2001;1510(1-2):152-166.
[21]. J. Wang, L. Kong, R. Guo, S. He, X. Liu, L. Zhang et al. Multifunctional icariin and tanshinone IIA co-delivery liposomes with potential application for Alzheimer’s disease. Drug Delivery. 2022;29(1):1648-1662
[22]. J. Smith, E. Wood, M. Dornish. Effect of chitosan on epithelial cell tight junctions. Pharmaceutical Research. 2004;21(1):43–9.
[23]. W. Wang, M. Liu, W. Gao, Y. Sun, X. Dong. Coassembled chitosan–hyaluronic acid nanoparticles as a theranostic agent targeting alzheimer’s β-amyloid. ACS Applied Materials & Interfaces. 2021;13(47):55879–89.
[24]. S. Saleem, R. Banerjee, R. Rajesh Kannan. Chrysin-loaded chitosan nanoparticle-mediated neuroprotection in AΒ1–42-induced neurodegenerative conditions in zebrafish. ACS Chemical Neuroscience. 2022;13(13):2017–34.
[25]. Z. Xing, J. Gauldie, G. Cox, H. Baumann, M. Jordana, X.F. Lei, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. Journal of Clinical Investigation. 1998;101(2):311–20.
[26]. E.M. Mantawy, A. Esmat, W.M. El-Bakly, R.A. Salah ElDin, E. El-Demerdash. Mechanistic clues to the protective effect of chrysin against doxorubicin-induced cardiomyopathy: Plausible roles of p53, MAPK and Akt pathways. Scientific Reports. 2017;7(1).
[27]. M. D'Amelio, V. Cavallucci, S. Middei, C. Marchetti, S. Pacioni, A. Ferri, et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of alzheimer's disease. Nature Neuroscience. 2010;14(1):69–76.
[28]. N. Dhas, T. Mehta. Cationic biopolymer functionalized nanoparticles encapsulating lutein to attenuate oxidative stress in effective treatment of alzheimer’s disease: A non-invasive approach. International Journal of Pharmaceutics. 2020;586:119553.
[29]. N. dos Santos Tramontin, S. da Silva, R. Arruda, K. Ugioni, P. Canteiro, G. de Bem Silveira et al. Gold Nanoparticles Treatment Reverses Brain Damage in Alzheimer’s Disease Model. Molecular Neurobiology. 2019;57(2):926-936.
[30]. R. Vandebriel, S. Remy, J. Vermeulen, E. Hurkmans, K. Kevenaar, N. Bastús et al. Pathways Related to NLRP3 Inflammasome Activation Induced by Gold Nanorods. International Journal of Molecular Sciences. 2022;23(10):5763.
[31]. P. Chakrabarty, K. Jansen-West, A. Beccard, C. Ceballos‐Diaz, Y. Levites, C. Verbeeck et al. Massive gliosis induced by interleukin-6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. The FASEB Journal. 2009;24(2):548-559.
[32]. A. A. te Velde, R.J. Huijbens, K. Heije, J.E. de Vries, C.G. Figdor. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood. 1990;76(7):1392–7.
[33]. J. Zhang, R. Liu, D. Zhang, Z. Zhang, J. Zhu, L. Xu, et al. Neuroprotective effects of maize tetrapeptide-anchored gold nanoparticles in alzheimer’s disease. Colloids and Surfaces B: Biointerfaces. 2021;200:111584.
[34]. R. He, M. Liu, Z. Zou, M. Wang, Z. Wang, X. Ju, et al. Anti-inflammatory activity of peptides derived from millet bran in vitro and in vivo. Food & Function. 2022;13(4):1881–9.
[35]. Z. Chen, W. Li, R.K. Santhanam, C. Wang, X. Gao, Y. Chen, et al. Bioactive peptide with antioxidant and anticancer activities from black soybean [glycine max (L.) Merr.] byproduct: Isolation, identification and Molecular Docking Study. European Food Research and Technology. 2018;245(3):677–89.
[36]. M. Sanati, S. Aminyavari, F. Khodagholi, M.J. Hajipour, P. Sadeghi, M. Noruzi, et al. Pegylated superparamagnetic iron oxide nanoparticles (spions) ameliorate learning and memory deficit in a rat model of alzheimer’s disease: Potential participation of stims. NeuroToxicology. 2021;85:145–59.
[37]. D. Kim, H. Kwon, T. Hyeon. Magnetite/Ceria Nanoparticle Assemblies for Extracorporeal Cleansing of Amyloid-β in Alzheimer's Disease. Advanced Materials. 2019;31(19):1807965.
[38]. B. Nelson, M. Johnson, M. Walker, K. Riley, C. Sims. Antioxidant Cerium Oxide Nanoparticles in Biology and Medicine. Antioxidants. 2016;5(2):15.
Cite this article
Yang,X. (2023). Applications of Nanotechnology in the Treatment of Alzheimer’s Disease. Theoretical and Natural Science,4,119-133.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part II
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).